Price (90d)
$87.16Signal Score (90d)
57Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $36.36B | $4.80B | $3.75 |
| 2025 | $33.54B | $4.66B | $3.63 |
| 2024 | $32.36B | $3.68B | $2.77 |
| 2023 | $31.23B | $3.76B | $2.83 |
| 2022 | $31.69B | $5.04B | $3.75 |
Social Signal Score
Earnings
Tue, Sep 1(in 2 weeks)
Consensus estimate $1.39 per share
Typical surprise +2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jun 3$1.55 vs $1.54beat
- Tue, Feb 17$1.36 vs $1.34beat
- Tue, Nov 18$1.36 vs $1.31beat
- Tue, Aug 19$1.26 vs $1.23beat
- Wed, May 21$1.62 vs $1.58beat
- Tue, Feb 18$1.39 vs $1.36beat
Estimates and results for MDT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MDT's reported EPS growth of 0.0% a year over 4 years.
- EPS in 5 years
- $3.74
- Implied price
- $82.38
- Return from $91.27
- -2.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $40.96 — -55.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -10.0% | -17.3% | -14.4% | -11.8% | -9.5% | -7.5% |
| -5.0% | -12.7% | -9.6% | -6.9% | -4.5% | -2.3% |
| 0.0% | -8.1% | -4.9% | -2.0% | 0.5% | 2.8% |
| 5.0% | -3.5% | -0.1% | 2.9% | 5.5% | 8.0% |
| 10.0% | 1.1% | 4.7% | 7.8% | 10.6% | 13.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- Newszacks.com·2d ago·Neutral
Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·4d ago·Negative
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know In the closing of the recent trading day, Medtronic (MDT) stood at $89.41, denoting a +2.58% move from the preceding trading day.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Medtronic: Buy This Undervalued Dividend Aristocrat Before The Market Catches On Medtronic is rated 'Buy' for its compelling combination of income, growth, and value. MDT's growth is led by cardiac ablation with 124% U.S. segment growth and rapid expansion of the Hugo robotic surgery platform. Management guides for 11.75% organic revenue growth in Q1 2027, with CAS expected to outpace the market and Symplicity renal denervation gaining traction.
View source ↗ - Newsfool.com·6d ago·Positive
Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now? Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market.
View source ↗